Drug Database
TR

triamcinolone (Trivaris / Trivaris)

✓ Approved

Merck & Co. · NR3C1 · Small Molecule

What is triamcinolone?

triamcinolone is a small molecule developed by Merck & Co.. It is approved for therapeutic indications via others or injectable (others) or intraocular injection.

Drug Profile

Brand NamesTrivaris, Trivaris
CompanyMerck & Co.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteOthers, Injectable (Others), Intraocular Injection
StatusApproved

Mechanism of Action

Molecular Targets

triamcinolone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

triamcinolone is developed for 5 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersDiabetic retinal oedema✓ Approved
Eye disordersDiabetic retinopathy✓ Approved
Eye disordersRetinal vein occlusion✓ Approved
Eye disordersUveitis✓ Approved
Eye disordersCystoid macular oedema✓ Approved

Related Research Articles

PubMedEye (London, England)2026-09-19

Transient intraocular lens opacification after intravitreal triamcinolone injection.

Cardoso-Teixeira Pedro P, Duarte Lilianne L, Costa Ferreira Cláudia C

PubMedCureus2026-09-18

Haemorrhagic Occlusive Retinal Vasculitis Following Cataract Surgery Without Intraocular Vancomycin.

Grech Sarah S, Bezzina Alastair A, Calleja Andrea A

This paper reports a rare case of haemorrhagic occlusive retinal vasculitis (HORV) following cataract surgery in the absence of intraocular vancomycin, raising important considerations about alternative aetiologies and perioperative management. A 79-year-old male patient with a background of type 2 diabetes, benign prostatic hyperplasia and asthma experienced recurrent hypersensitivity reactions to topical mydriatics during preoperative assessments for right eye cataract surgery in the private sector. Surgery was ultimately performed without topical mydriatics; full mydriasis was achieved with the use of intracameral mydriatic agents and iris hooks. No intraocular vancomycin was administered. Postoperative care included standard antibiotic-steroid eye drops. Three days postoperatively, the patient presented with sudden, painless vision loss. Examination revealed extensive retinal haemorrhages, vasculitis, and macular ischaemia. Imaging confirmed widespread retinal vascular damage. Infectious and autoimmune screens were negative. A diagnosis of HORV was made, and the patient was treated with intravenous methylprednisolone, topical corticosteroids, and later sub-tenon triamcinolone. Partial visual improvement was observed. This case highlights the possibility of HORV in the absence of vancomycin, suggesting that other immune-mediated or hypersensitivity pathways, in response to different triggers, may contribute to its pathogenesis.

PubMedHCA healthcare journal of medicine2026-09-17

Blaschko-Linear Lupus Erythematosus in a Pediatric Patient.

Hall Marshall M, Mayer Olivia O, Lim Henry H, Wilkes Dustin V DV et al.

The lines of Blaschko represent epithelial cell migration during embryonic development. Rare forms of cutaneous lupus erythematosus may manifest along these lines, and lesions are termed Blaschko-linear lupus erythematosus (BLE). The purpose of this case study is to present a rare manifestation of linear cutaneous lupus erythematosus following the lines of Blaschko in a pediatric patient. To date, there are very few reports of BLE. We present a 17-year-old female with a 2-month history of a mildly tender growing lesion along the right nasofacial sulcus. The patient denied lesions elsewhere and any systemic, joint, or mucosal symptoms. A biopsy of the lesion was consistent with cutaneous lupus erythematosus. Given the distribution and pathology, the patient was diagnosed with BLE. The patient was treated with intralesional triamcinolone, topical pimecrolimus, and systemic hydroxychloroquine with an emphasis on strict photo-protection. Despite these therapies the patient's disease persisted.

PubMedRetinal cases & brief reports2026-09-17

A Minimally Invasive Needle-Free Modified Cut-Down Technique for Posterior Sub-Tenon's Corticosteroid Injection.

Rostomian Nairi N, Kaganovski Adriana A, Kamen Dan D, Holt Henry H et al.

To describe a minimally invasive needle-free modified cut-down technique for posterior sub-Tenon's corticosteroid injection that avoids blind orbital needle passage and is suitable for office-based retinal practice. A stepwise surgical technique is described for posterior sub-Tenon's triamcinolone delivery using a 1-2 mm conjunctival incision, blunt dissection along the scleral surface, and flexible 27-gauge cannula-based injection. The technique was successfully implemented in an outpatient retinal clinic setting. In initial clinical use, no intraoperative complications were encountered, and the procedure was well tolerated. This modified needle-free cut-down technique provides a reproducible method for posterior sub-Tenon's corticosteroid delivery in outpatient retinal practice while eliminating blind orbital needle passage. It may provide a more controlled alternative to traditional techniques while potentially reducing the risks associated with blind sharp orbital needle passage.

PubMedInternational journal of pharmaceutics2026-09-17

Evaluation of the impact of the dialysis setup used on the in vitro dissolution behaviour of parenteral drug suspensions.

Boralewski Tessa T, Auel Tobias T, Seidlitz Anne A

Long-acting injectable (LAI) parenteral formulations are becoming increasingly important in drug therapy. Therefore, reliable and discriminatory in vitro dissolution methods are needed to support formulation development and the selection of promising candidate formulations before clinical studies. In this study, triamcinolone acetonide suspensions were used as a model system to investigate how different experimental parameters influence dissolution behaviour in dialysis-membrane based setups. Drug suspensions were placed in dialysis adapters enclosed in regenerated cellulose membranes. The adapters were integrated into compendial dissolution systems (USP apparatus 1 and 2). The influence of adapter orientation, agitation, adapter size, and membrane molecular weight cut-off (MWCO) was systematically investigated. Adapter orientations were first compared under constant MWCO conditions. The effect of rotational speed was then studied separately for horizontal and vertical orientations. Adapters of different sizes were compared at constant MWCO, and membranes with different nominal MWCOs were evaluated for both orientations. The results showed that all investigated parameters influenced the dissolution behaviour. The largest differences were observed between the different adapter orientations, indicating that the experimental setup strongly affects the dissolution process. In addition, larger membrane surface areas resulted in faster dissolution, and increasing rotational speed also accelerated dissolution. Membranes with higher MWCO generally led to faster dissolution. Post hoc mathematical approaches were explored to describe the influence of rotational speed and membrane surface area and provided a first approximation of the observed trends. However, the influence of MWCO could not be adequately described. Overall, the results show that several experimental parameters affect dissolution in dialysis-based systems. A clear understanding of the underlying processes is therefore essential to select appropriate models and to develop robust and clinically relevant in vitro dissolution methods for long-acting injectable suspensions.

PubMedJournal of glaucoma2026-09-15

Intraoperative Triamcinolone Acetonide Injection During Ahmed Glaucoma Valve Surgery Suppresses the Occurrence of the Postoperative Hypertensive Phase.

Hirota Akira A, Asaoka Satoko S, Kuroda Kohei K, Hayashi Yusuke Y et al.

Intraoperative sub-plate injection of triamcinolone acetonide during Ahmed glaucoma valve implantation markedly reduced the incidence of the postoperative hypertensive phase without increasing complications. The objective of this study was to evaluate whether intraoperative sub-plate injection of triamcinolone acetonide (TA) during Ahmed glaucoma valve (AGV) implantation reduces postoperative hypertensive phase (HP) incidence. We included 182 eyes from 182 patients who underwent AGV implantation between June 2017 and December 2023 at five institutions in Japan and were followed for a minimum of 3 months. The eyes were divided into two groups: 103 eyes received intraoperative sub-plate TA injection (TA group), and 79 eyes did not (non-TA group). The HP was defined as an initial intraocular pressure reduction to ≤22 mm Hg within 1 week postoperatively, followed by an increase to >21 mm Hg on two or more occasions within 3 months. Fisher's exact test,nonparametric tests, and multivariate logistic regression were used for statistical analyses. HP occurred in 8 (7.8%) and 28 (35.4%) eyes in TA and non-TA groups, respectively (P<0.0001). Among the eyes with anterior chamber tube placement, no cases of HP were observed in the TA group, whereas 8 cases occurred in the non-TA group (P<0.0001). In pars plana cases, HP developed in 8 and 20 eyes in the TA and non-TA groups, respectively (P=0.016). Multivariate logistic regression analysis identified the absence of intraoperative TA injection as an independent risk factor for the HP (odds ratio: 0.16, P<0.0001). Intraoperative sub-plate TA injection may be associated with a reduced incidence of postoperative HP after AGV implantation.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about triamcinolone